Baxter International Inc. (BAX) Return on Invested Capital (ROIC): -1.79%
Is Baxter International Inc.’s return on invested capital (ROIC) high or low?
Baxter International Inc.'s return on invested capital (ROIC) of -1.79% is 697% below its 5-year average of 0.30%, around the middle of its 5-year range (-10.88%–8.07%).
The return on invested capital (ROIC) for Baxter International Inc. (BAX) is -1.79% as of Thursday, June 11, 2026. It is below its 12-month average by 106.94% (-0.86%).
BAX Return on Invested Capital (ROIC) Chart
BAX Average Return on Invested Capital (ROIC) Chart
BAX Current vs Average Return on Invested Capital (ROIC) Chart
BAX Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
-1.79%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-0.86%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-2.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
0.30%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
3.46%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
5.32%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
7.56%
CURRENT VS TTM AVG
-106.94%
CURRENT VS 3Y AVG
+31.48%
CURRENT VS 5Y AVG
-696.67%
CURRENT VS 10Y AVG
-151.72%
CURRENT VS 15Y AVG
-133.63%
CURRENT VS 20Y AVG
-123.67%
BAX Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baxter International Inc. (BAX) | $10.49B | -1.79% | -0.86% | -2.61% | 0.30% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 8.36% | 4.65% | 6.09% | 6.66% |
| Align Technology, Inc. (ALGN) | $12.56B | 9.94% | 9.96% | 10.13% | 11.66% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 2.04% | 2.21% | 2.35% | 2.39% |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | 6.02% | 9.35% | -2.77% | -9.72% |
| Hologic, Inc. (HOLX) | $16.97B | 7.35% | 8.59% | 9.78% | 13.56% |
| Moderna, Inc. (MRNA) | $18.40B | -29.70% | -31.12% | -12.69% | 0.19% |
| BioNTech SE (BNTX) | $21.81B | -3.14% | -4.79% | 9.55% | 20.42% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 35.46% | 38.26% | 37.51% | 36.01% |
| Waters Corporation (WAT) | $23.83B | 17.57% | 18.00% | 20.73% | 22.79% |
Capital Efficiency
ROIC
-1.8%
ROE
-18.2%
Baxter International Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Baxter International Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Baxter International Inc. (BAX)?
- The return on invested capital (ROIC) for BAX stock is -1.79%.
- Is Baxter International Inc.'s return on invested capital (ROIC) high or low?
- Baxter International Inc.'s return on invested capital (ROIC) of -1.79% is 697% below its 5-year average of 0.30%, around the middle of its 5-year range (-10.88%–8.07%).
- What is the TTM average return on invested capital (ROIC) for Baxter International Inc. (BAX)?
- The TTM average return on invested capital (ROIC) for BAX stock is -0.86%.
- What is the 3Y average return on invested capital (ROIC) for Baxter International Inc. (BAX)?
- The 3Y average return on invested capital (ROIC) for BAX stock is -2.61%.
- What is the 5Y average return on invested capital (ROIC) for Baxter International Inc. (BAX)?
- The 5Y average return on invested capital (ROIC) for BAX stock is 0.30%.
- What is the 10Y average return on invested capital (ROIC) for Baxter International Inc. (BAX)?
- The 10Y average return on invested capital (ROIC) for BAX stock is 3.46%.
- What is the 15Y average return on invested capital (ROIC) for Baxter International Inc. (BAX)?
- The 15Y average return on invested capital (ROIC) for BAX stock is 5.32%.
- What is the 20Y average return on invested capital (ROIC) for Baxter International Inc. (BAX)?
- The 20Y average return on invested capital (ROIC) for BAX stock is 7.56%.
Baxter International Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -1.79% |
| 2024-12-31 | 0.06% |
| 2023-12-31 | 2.16% |
| 2022-12-31 | -10.88% |
| 2021-12-31 | 4.18% |
| 2020-12-31 | 8.07% |
| 2019-12-31 | 11.36% |
| 2018-12-31 | 11.78% |
| 2017-12-31 | 4.99% |
| 2016-12-31 | 5.82% |
| 2015-12-31 | 2.32% |
| 2014-12-31 | 2.81% |
| 2013-12-31 | 1.98% |
| 2012-12-31 | 14.20% |
| 2011-12-31 | 16.14% |
| 2010-12-31 | 11.97% |
| 2009-12-31 | 17.14% |
| 2008-12-31 | 17.34% |
| 2007-12-31 | 14.70% |
| 2006-12-31 | 13.03% |
| 2005-12-31 | 11.46% |
| 2004-12-31 | 7.80% |
| 2003-12-31 | 10.04% |
| 2002-12-31 | 12.79% |
| 2001-12-31 | 11.63% |
| 2000-12-31 | 13.52% |
| 1999-12-31 | 11.83% |
| 1998-12-31 | 7.74% |
| 1997-12-31 | 9.17% |
| 1996-12-31 | 12.02% |
Related Metrics
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider